Company intelligence / Profile preview

Carver Biosciences

Boston, Massachusetts, United States

Ownership: Private
Development stage: Preclinical

Overview

Carver Biosciences is developing CRISPR-Cas13 based antivirals targeting RNA viruses. The company is currently investigating the use of CRISPR-Cas13 to target and destroy respiratory viruses at the RNA level. Their initial focus is on influenza A virus to develop their platform and therapeutics against multiple strains of flu virus.

Therapeutic areas: Infectious Diseases
Modalities: CRISPR-Cas13 gene therapy
Industry: Biotech

Beyond the preview

Go deeper on Carver Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carver Biosciences.

Explore the full profile